Amgen Inc. on Friday confirmed that 100 employees had been notified earlier this week that their jobs were being eliminated due to the company’s restructuring or outsourcing efforts.
A spokeswoman for the Thousand Oaks biotech giant said that most of the positions were in operations and in research and development, but did not specify if all the jobs were local. She said affected workers are eligible for severance and career transition services.
Separately, the Amgen said it has decided not to pursue its application in Europe to expand the allowed use of its bone drug Xgeva to prevent or delay the spread of bone cancer in men who have castrate-resistant prostate cancer. A regulatory advisory board, the Committee for Medicinal Products for Human Use, said the clinical data supplied by Amgen did not make a compelling enough case for the expanded use. Amgen said it would continue to study Xgeva as a bone cancer preventative.
Amgen shares on Friday closed up 12 cents, or less than 1 percent, to $116.32 on the Nasdaq.